Form 8-K - Current report:
SEC Accession No. 0000950170-25-036820
Filing Date
2025-03-11
Accepted
2025-03-11 07:05:08
Documents
13
Period of Report
2025-03-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-20250310.htm   iXBRL 8-K 62727
2 EX-99.1 vktx-ex99_1.htm EX-99.1 30306
3 GRAPHIC img201808844_0.jpg GRAPHIC 10141
  Complete submission text file 0000950170-25-036820.txt   227695

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20250310.xsd EX-101.SCH 23918
15 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20250310_htm.xml XML 4545
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 25725831
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)